January 07th, 2018 UPDATED

January 07th, 2018 UPDATED

Download ->->->-> https://urlgoal.com/2tsbeU

CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Jan. 7, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically, Alnylam will obtain global development and commercialization rights to its investigational RNAi therapeutics programs for the treatment of ATTR amyloidosis, including patisiran and ALN-TTRsc02. Sanofi will receive royalties based on net sales of these ATTR amyloidosis products. Sanofi will obtain global development and commercialization rights to fitusiran, an investigational RNAi therapeutic, currently in development for the treatment of people with hemophilia A and B. Global commercialization of fitusiran, upon approval, will be done by Sanofi Genzyme, the specialty care global business unit of Sanofi. Alnylam will receive royalties based on net sales of fitusiran products. With respect to other products falling under the RNAi therapeutics alliance, the material terms of the 2014 Alnylam-Sanofi Genzyme alliance remain unchanged.

Alnylam will fund all development and commercialization costs for patisiran and ALN-TTRsc02 going forward. There will be no additional milestones due to either company with respect to patisiran or ALN-TTRsc02. Sanofi intends to substantially complete the transition of its patisiran activities in regions outside the United States, Canada, and Western Europe, consistent with the original scope of its license rights to patisiran, by mid-2018.

The restructuring will enable Sanofi to assume full responsibility for development and commercialization of fitusiran, including costs. However, during the anticipated transition period Alnylam will fund such costs. Alnylam intends to substantially complete the transition of fitusiran to Sanofi by mid-2018. Sanofi will pay Alnylam a milestone of $50 million following dosing of the first patient in the ATLAS Phase 3 program for fitusiran.

Alnylam management will discuss this restructured alliance in a conference call on January 7, 2018 at 4:30 p.m. ET, 1:30 p.m. PT. A slide presentation will also be available on the Investors page of the Company's website, www.alnylam.com, to accompany the conference call. To access the call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) five minutes prior to the start time and refer to conference ID 3786228. A replay of the call will be available beginning at 7:30 p.m. ET, 4:30 p.m. PT on January 7, 2018. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and refer to conference ID 3786228.

Now is your chance to see history made - Witness the best figure skaters from across the country compete for the crown of U.S. champion in San Jose December 29, 2017 to January 7th, 2018!The 2018 Prudential U.S. Figure Skating Championships will serve as the final qualifying event prior to the selection of the U.S. Olympic Figure Skating Team that will represent Team USA Feb. 9-23, 2018 at the Olympic Winter Games PyeongChang 2018. All-Session and Champions Ticket Packages are on sale now and can be purchased online or by calling 408-977-4715. For general questions, email grouptickets@sharkssports.net or visit SkateSanJose2018.com.

Telugu Panchangam for Sunday, January 7, 2018 Hevilambi Nama Samvatsara Panchangam Daily Sheets with Tithi, Nakshtra, Rahukalam, Varjyam, Durmuhrtham. Check out Telugu Panchangam PDF Download links for Telugu Panchangam Calendars.

During this time, a letter from Australian woman Holly Butcher was going viral on social media. The 27-year-old died from a rare form of cancer on January 4th, 2018. Her final Facebook post listed her life lessons. It also advised people not to take their lives for granted.

Movies released in 2018 included Avengers: Infinity War, Black Panther, Jurassic World: Fallen Kingdom, Incredibles 2, Aquaman, Bohemian Rhapsody, Venom, Mission: Impossible - Fallout, Deadpool 2, Fantastic Beasts: The Crimes of Grindelwald, A Quiet Place, A Star Is Born and Halloween.

On January 6, 2018, CBP will deliver ACE Deployment G, Release 3B. At this point, ACE will become the system of record for all statements with the exception of Reconciliation statements. CBP will deliver Statements for Reconciliations as part of ACE Deployment G, Release 4 on February 24, 2018. The Reconciliation Statements Deployment plan may be found in the Reconciliations Information Notice.

For validation purposes, both the new ACE Statement reports and the legacy ACE Account Revenue reports will be available to importers and brokers in the ACE Reports production environment on December 9, 2017. From December 9, 2017 until January 6, 2018, the new ACE Statement reports will solely be for trade validation/testing and therefore not actionable. Please refer to the Reports Statements Comparison Instructions for more information.

The Automated Commercial System (ACS) will remain the system of record for all statements until Deployment G, Release 3B; the trade community will continue to file statements in ACS until January 6, 2018*.

**If the trade wants to make changes to the statement, they will use SU instead of HP as of Friday, January 5, 2018, 11:59pm EST. Exception, Reconciliation Statements will continue to require an HP for updates. The Reconciliation Statements Deployment plan may be found in the Reconciliations Information Notice.

Our dazzling Zoo Lights displays will be lit up along zoo trails nightly from 5-8pm from now through January 7th, 2018. We are offering this extended schedule to allow for maximum lights viewing during the holiday break. Please note that the zoo is closed on December 25th (Christmas Day). 1e1e36bf2d